Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil with neostigmine and atropine for reducing extubation complications in PACU
ChiCTR2400082338Phase 4Not yet recruiting
- Sponsor
- Anesthesiology Department of Jiangyin Hospital Affiliated to Nantong University
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remifentanil, neostigmine and atropine in post-extubation complication (4 arms), sponsored by Anesthesiology Department of Jiangyin Hospital Affiliated to Nantong University. Primary endpoint: Incidence of coughing and adverse reactions during PACU extubation. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
remifentanilneostigmineatropine
03
Conditions
post-extubation complication
Beyond the preview
Go deeper on ChiCTR2400082338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082338.